VIVUS (NASDAQ:VVUS) Upgraded by ValuEngine to “Hold”

VIVUS (NASDAQ:VVUS) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Thursday, ValuEngine reports.

Shares of NASDAQ VVUS traded down $0.08 during trading hours on Thursday, hitting $3.26. The company’s stock had a trading volume of 35,585 shares, compared to its average volume of 17,500. The stock has a market capitalization of $35.53 million, a PE ratio of -0.94 and a beta of 1.84. VIVUS has a 12 month low of $2.15 and a 12 month high of $7.10. The stock has a 50-day moving average price of $3.49.

VIVUS (NASDAQ:VVUS) last posted its earnings results on Tuesday, April 30th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.17) by $0.42. The business had revenue of $16.15 million during the quarter. On average, sell-side analysts expect that VIVUS will post -3.49 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Alambic Investment Management L.P. acquired a new position in VIVUS during the 1st quarter worth approximately $51,000. Spark Investment Management LLC acquired a new position in VIVUS during the 1st quarter worth approximately $98,000. Finally, Sterling Investment Advisors Ltd. acquired a new position in VIVUS during the 1st quarter worth approximately $42,000. 15.60% of the stock is currently owned by institutional investors.

VIVUS Company Profile

VIVUS, Inc operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol.

Recommended Story: Earnings Reports

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.